American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 29, Issue 5 , Pages 333-338 , September 2008

Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders

  • Pasquale Capaccio, MD

      Affiliations

    • Department of Otorhinolaryngological and Ophthalmological Sciences, University of Milan, Policlinico Foundation I.R.C.C.S., Milan, Italy
    • Corresponding Author InformationCorresponding author. Department of Otorhinolaryngological and Ophthalmological Sciences, University of Milan, Policlinico Foundation I.R.C.C.S., Via F. Sforza 35, 20122 Milan, Italy. Tel.: +39 0250320245; fax: +39 0250320248.
    • ,
  • Sara Torretta, MD

      Affiliations

    • Department of Otorhinolaryngological and Ophthalmological Sciences, University of Milan, Policlinico Foundation I.R.C.C.S., Milan, Italy
    • ,
  • Maurizio Osio, MD

      Affiliations

    • Neurologic Clinic, University of Milan, Hospital L. Sacco, Milan, Italy
    • ,
  • Davide Minorati, MD

      Affiliations

    • Radiology Unit, University of Milan, Hospital L. Sacco, Milan, Italy
    • ,
  • Francesco Ottaviani, MD

      Affiliations

    • Chair of Otorhinolaryngology, Department of Medical Sciences, University of Milan, Hospital L. Sacco, Milan, Italy
    • ,
  • Giuseppe Sambataro, MD

      Affiliations

    • Department of Otorhinolaryngological and Ophthalmological Sciences, University of Milan, Policlinico Foundation I.R.C.C.S., Milan, Italy
    • ,
  • Cristina Nascimbene, MD

      Affiliations

    • Neurologic Clinic, University of Milan, Hospital L. Sacco, Milan, Italy
    • ,
  • Lorenzo Pignataro, MD

      Affiliations

    • Department of Otorhinolaryngological and Ophthalmological Sciences, University of Milan, Policlinico Foundation I.R.C.C.S., Milan, Italy

Received 16 August 2007

References 

  1. Bushara KO. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment-botulinum toxin A injections of the parotid glands. Med Hypotheses. 1997;48:337–339
  2. DasGupta BR, Sugiyama HA. A common subunit structure in Clostridium botulinum type A, B, and E toxins. Biochem Biophys Res Commun. 1972;48:108–112
  3. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope. 2001;111:218–226
  4. Brin MF. Botulinum toxin therapy: basic science and overview of other therapeutic applications. In:  Blitzer A,  Binder WJ,  Boyd JB, et al. editor. Management of facial lines and wrinkles. Philadelphia: Lippincott Williams & Wilkins; 2002;p. 279–302
  5. Marchese-Ragona R, De Filippis C, Staffieri A, et al. Parotid gland fistula: treatment with botulinum toxin. Plast Reconstr Surg. 2001;107:886–887
  6. Guntinas-Lichius O. Injection of botulinum toxin type B for the treatment of otolaryngology patients with secondary treatment failure of botulinum toxin type A. Laryngoscope. 2003;113:743–745
  7. Turk-Gonzales M, Odderson IR. Quantitative reduction of salivary production with botulinum toxin type B injection into the salivary glands. Neurorehabil Neural Repair. 2005;19:58–61
  8. Sollner T, Bennett MK, Whiteheart S, et al. A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell. 1993;75:409–418
  9. Ellies M, Laskawi R, Rohrbach-Volland S, et al. Botulinum toxin to reduce salivary flow: selected indications for ultrasound-guided toxin application into salivary glands. Laryngoscope. 2002;112:82–86
  10. Ellies M, Gottstein U, Rohrbach-Volland S, et al. Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis. Laryngoscope. 2004;114:1856–1860
  11. Marchese-Ragona R, Galzignato PF, Marioni G, et al. Endoscopic diagnosis of rhino-parotid fistula and successful treatment with botulinum toxin. Laryngoscope. 2005;115:2062–2064
  12. Marchese-Ragona R, Marioni G, Restivo AD, et al. The role of botulinum toxin in postparotidectomy fistula treatment. A technical note. Am J Otolaryngol. 2006;27:221–224
  13. Capaccio P, Paglia M, Minorati D, et al. Diagnosis and therapeutic management of iatrogenic parotid sialocele. Ann Otol Rhinol Laryngol. 2004;113:562–564
  14. Capaccio P, Cuccarini V, Benicchio V, et al. Treatment of iatrogenic submandibular sialocele with botulinum toxin. Case report. Br J Oral Maxillofac Surg. 2007;45:415–417
  15. Arnaud S, Batifor D, Goudot P, et al. Nonsurgical management of traumatic injuries of the parotid gland and duct using type A botulinum toxin. Plast Reconstr Surg. 2006;117:2426–2430
  16. Porta M, Gamba M, Bertacchi G, et al. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry. 2001;70:538–540
  17. Dogu O, Apaydin D, Sevim S, et al. Ultrasound-guided versus “blind” intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg. 2004;106:93–96
  18. Drobik C, Laskawi R. Frey's syndrome: treatment with botulinum toxin. Acta Otolaryngol Stockh. 1995;115:459–461
  19. Laccourreye O, Muscatelo L, Naude C, et al. Botulinum toxin type A for Frey's syndrome: a preliminary prospective study. Ann Otol Rhinol Laryngol. 1998;107:52–55
  20. Laskawi R, Drobik C, Schonebeck C. Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome). Laryngoscope. 1998;108:381–384
  21. Restivo DA, Lanza S, Patti F, et al. Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A. Neurology. 2002;59:1971–1973
  22. Drummond P. Mechanism of gustatory flushing in Frey's syndrome. Clin Auton Res. 2002;12:144–146
  23. Van Weel C. Functional status in primary care: COOP/WONCA charts. Disabil Rehabil. 1993;15:96–101
  24. Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279–1281
  25. Shaw JE, Abbott CA, Tindle K, et al. A randomised controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating. Diabetologia. 1997;40:299–301
  26. Hokfelt T, Johansson O, Ljungdahl A, et al. Peptidergic neurones. Nature. 1980;284:515–521
  27. Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis. 2007;13:253–260
  28. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245–258
  29. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35–42
  30. Ellies M, Schutz S, Quondamatteo F, et al. Immunohistochemical investigations of the influence of botulinum toxin A on the immunoreactivity of nNOS in the parotid gland of the rat. J Oral Maxillofac Surg. 2006;64:397–401

PII: S0196-0709(07)00151-2

doi: 10.1016/j.amjoto.2007.10.003

American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 29, Issue 5 , Pages 333-338 , September 2008

Article Tools

* Image Usage & Resolution